Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for HeartSciences (HSCS) over the last 4 years, with Q4 2025 value amounting to $777192.0.

  • HeartSciences' Gains from Investment Securities rose 101527.71% to $777192.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $777192.0, marking a year-over-year increase of 21564.69%. This contributed to the annual value of $173659.0 for FY2025, which is 83069.83% up from last year.
  • As of Q4 2025, HeartSciences' Gains from Investment Securities stood at $777192.0, which was up 101527.71% from $777400.0 recorded in Q3 2025.
  • In the past 5 years, HeartSciences' Gains from Investment Securities registered a high of $777400.0 during Q3 2025, and its lowest value of $38796.0 during Q3 2022.
  • Its 4-year average for Gains from Investment Securities is $238584.2, with a median of $86802.0 in 2023.
  • As far as peak fluctuations go, HeartSciences' Gains from Investment Securities plummeted by 8049.41% in 2023, and later skyrocketed by 139319.09% in 2025.
  • Over the past 4 years, HeartSciences' Gains from Investment Securities (Quarter) stood at $510431.0 in 2022, then crashed by 80.49% to $99564.0 in 2023, then plummeted by 30.01% to $69686.0 in 2024, then soared by 1015.28% to $777192.0 in 2025.
  • Its Gains from Investment Securities was $777192.0 in Q4 2025, compared to $777400.0 in Q3 2025 and $173659.0 in Q2 2025.